CA3190764A1 - Methods for the prevention of cholesterol crystal embolization with cyclodextrins - Google Patents

Methods for the prevention of cholesterol crystal embolization with cyclodextrins

Info

Publication number
CA3190764A1
CA3190764A1 CA3190764A CA3190764A CA3190764A1 CA 3190764 A1 CA3190764 A1 CA 3190764A1 CA 3190764 A CA3190764 A CA 3190764A CA 3190764 A CA3190764 A CA 3190764A CA 3190764 A1 CA3190764 A1 CA 3190764A1
Authority
CA
Canada
Prior art keywords
cyclodextrin
individual
beta
amount
hydroxypropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3190764A
Other languages
English (en)
French (fr)
Inventor
Diana KERWIN
Jason CAMM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beren Therapeutics PBC
Original Assignee
Beren Therapeutics PBC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics PBC filed Critical Beren Therapeutics PBC
Publication of CA3190764A1 publication Critical patent/CA3190764A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3190764A 2020-08-27 2021-08-27 Methods for the prevention of cholesterol crystal embolization with cyclodextrins Pending CA3190764A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071243P 2020-08-27 2020-08-27
US63/071,243 2020-08-27
PCT/US2021/048075 WO2022047244A1 (en) 2020-08-27 2021-08-27 Methods for the prevention of cholesterol crystal embolization with cyclodextrins

Publications (1)

Publication Number Publication Date
CA3190764A1 true CA3190764A1 (en) 2022-03-03

Family

ID=80352440

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3190764A Pending CA3190764A1 (en) 2020-08-27 2021-08-27 Methods for the prevention of cholesterol crystal embolization with cyclodextrins

Country Status (11)

Country Link
US (1) US20230302042A1 (https=)
EP (1) EP4203973A4 (https=)
JP (1) JP2023543132A (https=)
KR (1) KR20230096976A (https=)
CN (1) CN116635007A (https=)
AU (1) AU2021331485A1 (https=)
BR (1) BR112023003490A2 (https=)
CA (1) CA3190764A1 (https=)
IL (1) IL300881A (https=)
MX (1) MX2023002420A (https=)
WO (1) WO2022047244A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
MX371073B (es) * 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.

Also Published As

Publication number Publication date
KR20230096976A (ko) 2023-06-30
EP4203973A4 (en) 2024-08-21
US20230302042A1 (en) 2023-09-28
BR112023003490A2 (pt) 2023-05-09
JP2023543132A (ja) 2023-10-13
MX2023002420A (es) 2023-07-11
IL300881A (en) 2023-04-01
CN116635007A (zh) 2023-08-22
EP4203973A1 (en) 2023-07-05
AU2021331485A1 (en) 2023-03-23
WO2022047244A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
KR102465046B1 (ko) 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
EA026567B1 (ru) Применение бардоксолон метила для лечения ожирения
JP7835735B2 (ja) シクロデキストリンによるコレステロール結晶塞栓症の治療方法
US9375483B2 (en) Stable liquid pharmaceutical composition containing piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt and the manufacturing method thereof
WO2016110225A1 (zh) 一种磺酰胺类药物组合物
US20230375576A1 (en) Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
US20230302042A1 (en) Methods for the prevention of cholesterol crystal embolization with cyclodextrins
WO2022199551A1 (en) Dc009 for treating acute ischemic stroke
RU2678967C1 (ru) Способ лечения больных атеросклерозом сосудов шеи и сосудов органов средостения
US9101640B2 (en) Use of Danshensu, Notoginsenoside R1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder
US20240000826A1 (en) Methods for the treatment of cardiovascular disease with cyclodextrins
MX2015002646A (es) Otamixaban para uso en el tratamiento de sindrome coronario agudo sin elevacion de st en pacientes programados para ser sometidos a injerto de bypass de arteria coronaria.
TW202342072A (zh) 以環糊精治療高三酸甘油脂血症之方法
JP2008509141A (ja) 非経口製剤の組織刺激を軽減させる方法及び組成物

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250813

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251015

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251230

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260211